Lilly to buy Merida Biosciences for up to $2.875B
What's the deal? Eli LillyDealroom has a profile for this one. Try Dealroom → has signed a definitive agreement to acquire Merida Biosciences, a biotech developing precision therapies for serious autoimmune and allergic diseases, for up to $2.875 billion in cash. The sum covers an upfront payment and contingent milestone payments. The deal is expected to close in the fourth quarter of 2026.
What does Merida do? It engineers biologics designed to selectively degrade pathogenic autoantibodies — the agents behind many immune-mediated conditions — while preserving normal immune function. That targets the biological cause of disease rather than broadly suppressing the immune system, as many current therapies do.
The lead asset: MER511 is in Phase 1 for Graves' disease and thyroid eye disease (TED), both driven by thyroid-stimulating autoantibodies. Graves' disease affects roughly 3 million people in the US, and 25% to 40% of them go on to develop TED, which can cause pain, disfigurement, and vision loss.
Merida's pipeline also includes MER769, a preclinical program targeting food allergy, asthma, chronic spontaneous urticaria, and other IgE-driven diseases, plus earlier work in kidney conditions such as membranous nephropathy.
What's the endgame? The acquisition strengthens Lilly's immunology capabilities. Initial Phase 1 data showed MER511 achieved "robust reductions in pathogenic thyroid-stimulating antibodies" with a favourable early safety profile.
"We're building our pipeline around therapies that meaningfully change the course of disease, not just its downstream effects," said Francisco Ramírez-Valle, senior vice president of Lilly immunology research and early clinical development.
What could go wrong? The transaction is subject to regulatory approvals and customary closing conditions. Its financial impact stays unknown until Lilly determines GAAP accounting treatment after closing.
The signal: Lilly is betting on precision biologics that target the antibodies causing disease directly. If the platform holds up beyond its lead program, it points to a broader shift away from blunt immune suppression toward more selective treatment of antibody-driven conditions.
Read more: stocktitan.net
Image credit: Generated with Gemini
